skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Molecular signals in antigen presentation. II. Activation of cytolytic cells in vitro after ultraviolet radiation or combined gamma and ultraviolet radiation treatment of antigen-presenting cells

Journal Article · · J. Immunol.; (United States)
OSTI ID:5386389

Murine low-density spleen cells have potent antigen-presenting ability in a hapten-specific cytolytic T lymphocyte (CTL) system using the hapten azobenzenearsonate (ABA). Exposure of these cells to 0.33 KJ/m/sup 2/ of ultraviolet radiation (UVR) after coupling to hapten results in markedly inhibited antigen-presenting function that can be substantially corrected or bypassed by interleukin 1 (IL 1). These results have been interpreted to reflect an inhibition of Lyt-1/sup +/ T cell activation by UVR-treated APC. Treatment of these cells sequentially with 1500 rad of ..gamma..-radiation (GR) prior to hapten coupling, followed by 0.33 KJ/m/sup 2/ of UVR radiation after coupling, results in an antigen-resenting defect only minimally improved by IL 1. However, partially purified interleukin 2 (IL 2) can completely bypass or correct this defect. Thus, combined Cr and UVR induces a different or more profound defect in APC function when compared to UVR alone. However, these cells do provide a signal(s) other than hapten necessary for CTL activation because ABA-coupled high density spleen cells do not activate CTL cells, even with the addition of IL 2. Fluorescence-activated cell sorter analysis demonstrates that exposure of these low density spleen cells to GP or UVR results in decreased I-A antigen expression at 24 hr; exposure to both GR and UVR results in a greater decrease in I-A antigen expression at 24 hr than either alone. The addition of nonhapten-coupled low-density APC partially reconstitutes the ability of combined GR/UVR-treated LD-APC to present antigen, and this effect is enhanced by the administration of exogenous IL 1.

Research Organization:
Harvard Medical School, Boston, MA
OSTI ID:
5386389
Journal Information:
J. Immunol.; (United States), Vol. 132:5
Country of Publication:
United States
Language:
English